{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-097317","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2025-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.442722+00:00","generated_at":"2026-05-17T04:23:18.191904+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Novavax completes Nuvaxovid EU marketing authorization transfer to Sanofi; triggers $25M milestone","bullets":["European Commission approved transfer of Nuvaxovid EU marketing authorization from Novavax CZ to Sanofi Winthrop Industrie.","Milestone payment of $25M triggered; Novavax expects receipt in Q1 2026.","Additional milestones: $25M for U.S. transfer, $75M for technology transfer, up to $350M for combo products.","Novavax eligible for tiered royalties on Sanofi's standalone COVID vaccine and combination products.","CEO John Jacobs: successful transfer is another step in ensuring global access to protein-based COVID vaccine."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-097317","json":"https://secwatch.observer/filing/0001104659-25-097317.json","markdown":"https://secwatch.observer/filing/0001104659-25-097317.md","text":"https://secwatch.observer/filing/0001104659-25-097317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925097317/0001104659-25-097317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925097317/tm2528134d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:23:18.191904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}